Showing 1881-1890 of 9336 results for "".
- FDA: Omeza's Collagen Matrix Cleared for Marketinghttps://practicaldermatology.com/news/fda-omezas-collagen-matrix-cleared-for-marketing/2460904/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Omeza Collagen Matrix for chronic wound care. Omeza Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant, and other p…
- Sciton Rolls Out BBLINK Goggles for Improved Eye Protectionhttps://practicaldermatology.com/news/sciton-rolls-out-bblink-goggles-for-improved-eye-protection/2460903/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technology which connects direct…
- New Melanoma Staging System May Better Predict Prognosishttps://practicaldermatology.com/news/new-melanoma-staging-system-may-better-predict-prognosis/2460901/A new system for classifying melanoma when the disease has spread to the lymph nodes may offer a better tool for predicting patients' outcomes and determining their treatment needs, according to research in JAMA Surgery. The current nine-tier system for lymph node staging in melanoma can be confus…
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%). Sun Pharma…
- Study: Dupixent Improves AD Symptoms in Kids As Young As Six Monthshttps://practicaldermatology.com/news/study-dupixent-improves-ad-symptoms-in-kids-as-young-as-six-months/2460898/Dupixent (dupilumab) significantly reduces signs and symptoms of moderate-to-severe atopic dermatitis in children as young as six months, a new study shows. The trial met its primary and all secondary endpoints, showing that Dupixent added to standard-of-care topical corticosteroids (TCS) signific…
- Business News: Crown Labs to Acquire StriVectinhttps://practicaldermatology.com/news/business-news-crown-labs-acquire-strivectin/2460897/Crown Laboratories is slated to acquire StriVectin from the private equity firm L Catterton. The transaction is expected to close by mid-September and is subject to regulatory approvals and other customary closing conditions. Terms of the transaction were not disclosed. StriVectin’s products will…
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation "Over three million people are diagnosed with skin cancer each year and many of these cases could have been prevented with proper sun protection," says Stephen Sandecki, Principal at UV …
- New Gel Shows Promise Against BCChttps://practicaldermatology.com/news/new-gel-shows-promise-against-bcc/2460890/Medivir AB’s topical histone deacetylase (HDAC) inhibitor remetinostat performed well in a phase II study in basal cell carcinoma (BCC), according to research published online in Clinical Cancer Research. The new gel could reduce the need for surgical removal of BCC lesions, which can be a costly…
- New Survey: Americans Have Missed Out on Dating, Parties, School And Work Because of Acnehttps://practicaldermatology.com/news/new-survey-americans-have-missed-out-on-dating-parties-school-and-work-because-of-acne/2460889/Americans missed out on dating, school and hanging out with friends because of acne during the past year, according to a new survey by University Medical, the manufacturer of the Acne Wipeout skincare system. After more than a year of looking at themselves on screens and hiding behind social media…
- MoonLake Immunotherapeutics Taps Former Kymab CEO Simon Sturge as Chairman and Spike Loy for the Board of Directorshttps://practicaldermatology.com/news/moonlake-immunotherapeutics-taps-former-kymab-ceo-simon-sturge-as-chairman-and-spike-loy-for-the-board-of-directors/2460887/Simon Sturge is the new Chairman of MoonLake Immunotherapeutics AG, and Spike Loy has joined the Company’s Board of Directors. Mr. Sturge has 40 years of international leadership experience in the biotechnology and pharmaceutical industry. Most recently, he was Chief Executive Officer of Kymab, a…